



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
Attorney Docket No. 01139/3/US

Application Of: Allenspach et al.

Serial No.
10/647,501

Filing Date
August 25, 2003

Examiner
Unknown

Group Art Unit
Unknown

Title: **PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG RELEASE PROFILE**

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:


Supplemental Information Disclosure Statement Under 37 CFR 1.97-1.98; Form 1449 citing 5 references; Itemized postcard.

in the above identified application.

- ☐ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. _____
as described below.

19-1025


- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.


Signature

Dated: March 1, 2004

Kenton N. Fedde, Reg. No. 54,701

I certify that this document and fee is being deposited
March 1, 2004 with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.



Signature of Person Mailing Correspondence

Kenton N. Fedde

Typed or Printed Name of Person Mailing Correspondence

CC:



Case 01139/3/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Allenspach et al.

SERIAL NO.: 10/647,501

FILED: August 25, 2003

GROUP ART UNIT: Unknown

EXAMINER: Unknown

DATE: March 1, 2004

TITLE: PHARMACEUTICAL COMPOSITION EXHIBITING CONSISTENT DRUG
RELEASE PROFILE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents
Box 1450
Alexandria, VA 22313

Sir:


This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement previously filed. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

These newly cited documents are as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Kenton N. Fedde
Attorney for Applicants
Registration No. 54,701
(314) 274-5402 (St. Louis)

Pharmacia Corporation
Global Patent Department
Post Office Box 1027
St. Louis, MO 63006



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 01139/3/US	APPLICATION NO.: 10/647,501
	INVENTOR: Allenspach et al.	
	Filed: 08/25/2003	Group: Unknown

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4 3 6 9 3 0 8	01/18/83	Trubiano	536/106		07/24/81
	4 5 1 7 1 7 9	05/14/85	Raghunathan	514/249		03/06/84
	5 1 6 4 0 1 4	11/17/92	Brancq et al.	127/32		05/15/90

FOREIGN PATENT DOCUMENTS

Examiner Initial												Translation	
	Document Number	Date	Country	Class	Subclass	Yes	No						
	WO 9 3 2 1 0 0 8	10/28/93	PCT	B30B	11/26	X							
	EP 0 9 3 3 0 7 9	08/04/99	Europe	A61Ks	9/20	X							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)